Applied dna announces notice of allowance for u.s. patent covering fundamental aspect of its linea(tm) ivt platform

Patent covers the composition of the company's proprietary linea™ rnap, a core technology empowering the linea™ ivt platform patent application also currently pending in key international markets stony brook, ny / accesswire / june 5, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna or the "company"), a leader in pcr-based dna technologies, announced today that it received a notice of allowance from the united states patent and trademark office (uspto) for patent application 18/302,247, entitled "compositions and methods for rna synthesis." the resulting patent will cover the composition of the company's chemically modified rna polymerase enzyme branded linea™ rnap, with expected patent protection into 2041.
DNA Ratings Summary
DNA Quant Ranking